The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy
Open accessAbstract
UNLABELLED: Parkinson disease (PD), progressive supranuclear palsy (PSP), and multiple-system atrophy (MSA) are known to affect dopaminergic neurons of the brain stem and striatum with different preferential involvement. Here we investigated differences in striatal subregional dopamine transporter loss in PD, PSP, and MSA and assessed the diagnostic value of (18)F-fluorinated-N-3-fluoropropyl-2-β-carboxymethoxy-3-β-(4-iodophenyl)nortropane ((18)F-FP-CIT) PET in differentiating PSP and MSA from PD. METHODS: Forty-nine patients with PD, 19 patients with PSP, 24 patients with MSA, and 21 healthy people (healthy controls) were examined with (18)F-FP-CIT PET. The PET images were spatially normalized and analyzed with 12 striatal subregional volume-of-interest (VOI) templates (bilateral ventral striatum [VS], anterior caudate [AC], posterior caudate, anterior putamen, posterior putamen [PP], and ventral putamen [VP]) and 1 occipital VOI template. The nondisplaceable binding potential (BP(ND)) and intersubregional ratio (ISR; defined as the ratio of the BP(ND) of one striatal subregion to that of another striatal subregion) of subregional VOIs were calculated. RESULTS: The BP(ND) of all VOIs in the PD, MSA, and PSP groups were significantly lower than those in the healthy controls (P < 0.05). The BP(ND) of AC and the AC/VS ISR in the PSP group were significantly lower than those in the PD group. The BP(ND) of VP was significantly lower, but the PP/VP ISR was significantly higher in the MSA group than in the PD group. At the cutoff value for the AC/VS ISR (<0.7), the sensitivity and specificity for differentiating PSP from PD were 94% and 92%, respectively. At the cutoff value for the PP/VP ISR (>0.65), the sensitivity and specificity for differentiating MSA from PD were 90% and 45%, respectively. The diagnostic accuracy of visual analysis was similar to that of quantitative analysis for differentiating PSP from PD but was significantly higher for differentiating MSA from PD. CONCLUSION: Compared with PD, PSP and MSA showed more prominent and earlier dopamine transporter loss in the AC and VP, respectively. These findings could be useful for suggesting PSP or MSA in parkinsonian cases without characteristic atypical features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“This pattern may reflect the neuropathologic basis of PD, in which the particularly early involvement of the ventrolateral part of the pars compacta of the substantia nigra, which projects to the posterior part of the putamen, is known to occur (28).”
BackgroundSecond consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140 · cited 2×
“PD (49) 46 (94) 2 (4) 1 (2) PSP (19) 2 (11) 15 (78) 2 (11) MSA (24) 5 (21) 3 (12) 16 (67)”
Haber, S. N., Fudge, J. L., & McFarland, N. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-02369.2000 · Cited by 1,610
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
Multiple system atrophy: A review of 203 pathologically proven cases
Wenning, G. K., Tison, F., ben Shlomo, Y., Daniel, S. E., & Quinn, N. P. (1997) · Movement Disorders · doi:10.1002/mds.870120203 · Cited by 803
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Del Tredici, K. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 538
Mawlawi, O., Martinez, D., Slifstein, M., Broft, A., Chatterjee, R., Hwang, D.-R., Huang, Y., Simpson, N., Ngo, K., Van Heertum, R., et al. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200109000-00002 · Cited by 525 · cited 1×
“The VOI for the ventral striatum (VS) was defined on the basis of previously defined criteria (22); the caudate nucleus and putamen were further divided into 5 subregions: anterior caudate (AC), posterior caudate (PC), anterior putamen (AP), PP, and ventral putamen (VP).”
MethodSeibyl, J. P., Marchek, K. L., Quinlan, D., Sheff, K., Zoghbi, S., Zea‐Ponce, Y., Baldwin, R. M., Fussell, B., Smith, E. O., Charney, D. S., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380407 · Cited by 467
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis
Tang, C. C., Poston, K. L., Eckert, T., Feigin, A., Frucht, S., Gudesblatt, M., Dhawan, V., Lesser, M., Vonsattel, J.-P., Fahn, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70002-8 · Cited by 354
Litvan, I., Agid, Y., Jankovic, J., Goetz, C., Brandel, J. P., Lai, E. C., Wenning, G., D'Olhaberriague, L., Verny, M., Chaudhuri, K. R., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.922 · Cited by 350
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2009) · Brain · doi:10.1093/brain/awn291 · Cited by 347
Dual-Modality Imaging: Combining Anatomy and Function
Townsend, D. W. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.051276 · Cited by 282
Litvan, I. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550200007003 · Cited by 213
Pirker, W., Asenbaum, S., Bencsits, G., Prayer, D., Gerschlager, W., Deecke, L., & Br�cke, T. (2000) · Movement Disorders · doi:10.1002/1531-8257(200011)15:6<1158::aid-mds1015>3.0.co;2-0 · Cited by 206
Kim, Y. J., Ichise, M., Ballinger, J. R., Vines, D., Erami, S. S., Tatschida, T., & Lang, A. E. (2002) · Movement Disorders · doi:10.1002/mds.10042 · Cited by 191
Brücke, T., Asenbaum, S., Pirker, W., Djamshidian, S., Wenger, S., Wöber, C., Müller, C., & Podreka, I. (1997) · PubMed · Cited by 186
Varrone, A., Marek, K. L., Jennings, D., Innis, R. B., & Seibyl, J. P. (2001) · Movement Disorders · doi:10.1002/mds.1256 · Cited by 166
Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT
Brücke, T., Asenbaum, S., Pirker, W., Djamshidian, S., Wenger, S., Wöber, C., Müller, C., & Podreka, I. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_2 · Cited by 160
Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease
Morrish, P., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.6.2097 · Cited by 153
Fundamentals of Positron Emission Tomography and Applications in Preclinical Drug Development
Cherry, S. R. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010357 · Cited by 153
The differential diagnosis of Parkinson's disease
Poewe, W. H., & Wenning, G. K. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.3.x · Cited by 153
Koch, W., Radau, P. E., Hamann, C., & Tatsch, K. (2005) · PubMed · Cited by 128
Dystonia in progressive supranuclear palsy.
Barclay, C. L., & Lang, A. E. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.4.352 · Cited by 126
Scherfler, C., Seppi, K., Donnemiller, E., Goebel, G., Brenneis, C., Virgolini, I. J., Wenning, G. K., & Poewe, W. H. (2005) · Brain · doi:10.1093/brain/awh485 · Cited by 125
The clinical features of Parkinson's disease in 100 histologically proven cases.
Aj, H., Daniel, S. E., & Lees, A. J. (1993) · PubMed · Cited by 121
Lyoo, C. H., Jeong, Y., Ryu, Y. H., Lee, S., Song, T., Lee, J. H., Rinne, J. O., & Lee, M. S. (2008) · Brain · doi:10.1093/brain/awm328 · Cited by 91
Wang, J., Zuo, C.-T., Jiang, Y., Guan, Y., Chen, Z., Xiang, J.-D., Yang, L.-Q., Ding, Z., Wu, J.-J., & Su, H.-L. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0322-9 · Cited by 90
Clinical correlates of the pathology underlying parkinsonism: A population perspective
Bower, J. H., Dickson, D. W., Taylor, L. M., Maraganore, D. M., & Rocca, W. A. (2002) · Movement Disorders · doi:10.1002/mds.10202 · Cited by 80
One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system
Lee, S. J., Oh, S. J., Chi, D. Y., Kang, S. H., Kil, H. S., Kim, J. S., & Moon, D. H. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.02.007 · Cited by 72
Self-citationJokinen, P., Helenius, H., Rauhala, E., Brück, A., Eskola, O., & Rinne, J. O. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061572 · Cited by 72
Messa, C., Volonté, M. A., Fazio, F., Zito, F., Carpinelli, A., d’Amico, A., Rizzo, G., Moresco, R. M., Paulesu, E., Franceschi, M., et al. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050295 · Cited by 65
Automated template-based PET region of interest analyses in the aging brain
Sun, F. T., Schriber, R. A., Greenia, J. M., He, J., Gitcho, A., & Jagust, W. J. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.09.022 · Cited by 58
Progression of parkinsonism in multiple system atrophy
Seppi, K., Yekhlef, F., Diem, A., Wolf, E., Mueller, J., Tison, F., Quinn, N. P., Poewe, W. H., & Wenning, G. K. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0617-2 · Cited by 58
Nigral burden of α‐synuclein correlates with striatal dopamine deficit
Kovács, G. G., Milenković, I., Preusser, M., & Budka, H. (2008) · Movement Disorders · doi:10.1002/mds.22207 · Cited by 57
Yagi, S., Yoshikawa, E., Futatsubashi, M., Yokokura, M., Yoshihara, Y., Torizuka, T., & Ouchi, Y. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076802 · Cited by 53
Goto, S., Matsumoto, S., Ushio, Y., & Hirano, A. (1996) · Neurology · doi:10.1212/wnl.47.4.1032 · Cited by 48
Im, J., Chung, S. J., Kim, J., & Lee, M. C. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.01.006 · Cited by 39
Self-citationExcessive dopamine neuron loss in progressive supranuclear palsy
Murphy, K. E., Karaconji, T., Hardman, C. D., & Halliday, G. M. (2007) · Movement Disorders · doi:10.1002/mds.21907 · Cited by 37
CADASIL syndrome in a large Turkish kindred caused by the R90C mutation in the Notch3 receptor
Utku, U., Çelik, Y., Uyguner, Z. O., Yüksel‐Apak, M., & Wollnik, B. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00344.x · Cited by 36
Cited by
Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
Whitwell, J. L., Höglinger, G. U., Antonini, A., Bordelon, Y., Boxer, A. L., Colosimo, C., van Eimeren, T., Golbe, L. I., Kassubek, J., Kurz, C., et al. (2017) · Movement Disorders · doi:10.1002/mds.27038 · Cited by 260
Christine, C. W., Richardson, R. M., Van Laar, A. D., Thompson, M. E., Fine, E. M., Khwaja, O. S., Li, C., Liang, G. S., Meier, A., Roberts, E. W., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000012952 · Cited by 89
Gut Microbiota-Derived Metabolite Trimethylamine N-Oxide as a Biomarker in Early Parkinson’s Disease
Chung, S. J., Rim, J. H., Ji, D., Lee, S., Yoo, H. S., Jung, J. H., Baik, K., Choi, Y., Ye, B. S., Sohn, Y. H., et al. (2021) · Nutrition · doi:10.1016/j.nut.2020.111090 · Cited by 74
Metadata
- Authors
- Oh, M., Kim, J. S., Kim, J. Y., Shin, K.-H., Park, S. H., Kim, H. O., Moon, D. H., Oh, S. J., Chung, S. J., & Lee, C. S.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-02-09
- Volume
- 53
- Issue
- 3
- Pages
- 399-406
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2133149158
- Cited by
- 276
- References
- 40
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.